Stock Screener App

Frei - Play StoreApp Store

Installieren Installieren

Dow:

Nasdaq:

S&P 500:

INCY

$120.393.07%3.59

Nachbörslich: 120.41+0.02 +0.02%

Incyte Corp (INCY)

Date: O: H: L: C: Vol:

Incyte Corp Aktie (INCY) Neueste Nachrichten

MTAK Price Today: Market Technology Acquisition Corp. Stock Price, Quote & Chart | MEXC - MEXC

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy - Zacks Investment Research

An experimental drug combination showed a 71% response rate in colorectal cancer. - Stock Titan

Incyte Corp. Company & People | INCY - Barron's

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Via TT

Incyte (NasdaqGS:INCY) Stock Price - Simply Wall Street

Incyte Corp. Research & Ratings | INCY - Barron's

Incyte Corp. Advanced Charts | INCY - Barron's

Incyte Corp. Financials | INCY - Barron's

Incyte plans to publish third-quarter results at 7 a.m. Oct. 29, then hold a call at 8. - Stock Titan

Incyte Corporation (INCY) Stock Forecasts - Yahoo Finance

Incyte Corp. Stock Grades | INCY - Barron's

Form 4 Incyte Corporation For: 2 October By Investing.com - Investing.com Canada

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - Yahoo Finance

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - The Globe and Mail

INCY or TECH: Which Is the Better Value Stock Right Now? - Zacks Investment Research

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - TradingView

A legal chief with more than 25 years in pharma and biotech joins MiniMed. - Stock Titan

Mission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx Summit - Business Wire

About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment. - Stock Titan

Incyte will present research on eczema, vitiligo and painful skin conditions in Vienna - Stock Titan

More than 1 million patients have used this skin cream. Partners plan to bring it to Australia. - Stock Titan

Incyte Genomics Inc (INCY) Revenue 2025: $5.1B, up 21.2% - Stock Titan

Incyte Genomics Inc (INCY) Total Assets 2025: $7.0B, up 27.8% - Stock Titan

Incyte Genomics Inc (INCY) EPS 2025: $6.41, up 4173.3% - Stock Titan

Incyte Genomics Inc (INCY) Net Income 2025: $1.3B, up 3846.9% - Stock Titan

Incyte (INCY): 3 Reasons We Love This Stock - Yahoo Finance

Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today - Benzinga

Cantor Fitzgerald reiterates Neutral on Incyte stock after conference - Investing.com

Profitable Biotech Incyte Stock Forms Handle Amid Strong Institutional Accumulation - Investor's Business Daily

Cantor Fitzgerald reiterates Neutral on Incyte stock after conference By Investing.com - Investing.com South Africa

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Incyte at Cantor conference: pipeline advances, post-Jakafi plan - investing.com

Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program - Yahoo Finance

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com India

Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - investing.com

Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com UK

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup - ChartMill

Incyte Corp. (INCY) Peer Comparison – Compare with Others - Value Research

Incyte Corp. (INCY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Incyte (INCY) Institutional Ownership 2026 $INCY - MarketBeat

Incyte Corp. (INCY) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com

2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off - The Globe and Mail

Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

H.C. Wainwright reiterates Incyte stock rating on Medicaid pricing deal - Investing.com

Incyte to Present at Upcoming Investor Conferences - Yahoo Finance

BMO reiterates Incyte stock rating on CMS pricing agreement - Investing.com

Ähnlich wie INCY

INSM$112.580.89%

BNTX$88.171.08%

ROIV$36.911.63%

ALNY$165.005.17%

RPRX$67.181.90%

EXEL$69.394.82%